NCT02210494 is a Phase 1 clinical trial of Secretrol in EMR Ulcer, sponsored by Effexus Pharmaceutical.

Who is sponsoring NCT02210494?

NCT02210494 is sponsored by Effexus Pharmaceutical.

What drugs are being tested in NCT02210494?

Interventions in NCT02210494: Secretrol.

Is NCT02210494 still recruiting?

NCT02210494 is currently status unknown. Last updated 4 August 2014.

Last reviewed 2014-08-04 · How we verify

NCT02210494

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Study of Safety of Secretrol® in the Short-term Management of Patients Undergoing Endoscopic Mucosal Resection (EMR)

Status unknown Phase 1 Last updated 4 August 2014

What this trial tests

Phase 1 trial testing Secretrol in EMR Ulcer in 5 participants. Status unknown.

Timeline

1 April 2013

Primary endpoint
1 August 2015

Quick facts

Lead sponsor	Effexus Pharmaceutical
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	1 April 2013
Primary completion	1 August 2015
Sites	1 location across United States

Drugs / interventions tested

Secretrol — full drug profile →

Conditions studied

EMR Ulcer — all drugs for EMR Ulcer →

Sponsor

Effexus Pharmaceutical — full company profile →

Who can join

18 and older, any sex, with EMR Ulcer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Adverse effect evaluation
Time frame: 60 days

Sponsor's own description

Evaluate the safety of Secretrol® in patients undergoing endoscopic mucosal resection for early adenocarcinoma of the esophagus.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02210494 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Effexus Pharmaceutical
Last refreshed: 4 August 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02210494.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing